The CNS relapse in T-cell lymphoma index predicts CNS relapse in patients with T- and NK-cell lymphomas-Reference-Cited by-同舟云学术

The CNS relapse in T-cell lymphoma index predicts CNS relapse in patients with T- and NK-cell lymphomas

Published:2024-06-28 Issue:13 Volume:8 Page:3507-3518
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Bhansali Rahul S.¹^ORCID,Ellin Fredrik²,Relander Thomas³⁴,Cao Miao¹^ORCID,Li Wenrui⁵^ORCID,Long Qi⁵,Ganesan Nivetha⁶,Stuver Robert⁶^ORCID,Horwitz Steven M.⁶,Wudhikarn Kitsada⁷⁸,Hwang Steven R.⁷^ORCID,Bennani N. Nora⁷^ORCID,Chavez Julio⁹,Sokol Lubomir⁹,Saeed Hayder⁹^ORCID,Duan Frank¹⁰,Porcu Pierluigi¹¹^ORCID,Pullarkat Priyanka¹²,Mehta-Shah Neha¹³^ORCID,Zain Jasmine M.¹⁴^ORCID,Ruiz Miguel¹⁵,Brammer Jonathan E.¹⁵,Prakash Rishab¹⁶,Iyer Swaminathan P.¹⁶,Olszewski Adam J.¹⁷^ORCID,Major Ajay¹⁸,Riedell Peter A.¹⁹,Smith Sonali M.¹⁹^ORCID,Goldin Caroline²⁰,Haverkos Bradley¹⁸^ORCID,Hu Bei²¹^ORCID,Zhuang Tony Z.²²^ORCID,Allen Pamela B.²²^ORCID,Toama Wael²³^ORCID,Janakiram Murali²³,Brooks Taylor R.²⁴^ORCID,Jagadeesh Deepa²⁴,Hariharan Nisha²⁵,Goodman Aaron M.²⁵,Hartman Gabrielle²⁶,Ghione Paola⁶^ORCID,Fayyaz Fatima²⁷^ORCID,Rhodes Joanna M.²⁷^ORCID,Chong Elise A.¹^ORCID,Gerson James N.²⁸,Landsburg Daniel J.¹,Nasta Sunita D.¹,Schuster Stephen J.¹,Svoboda Jakub¹,Jerkeman Mats³⁴,Barta Stefan K.¹^ORCID

Affiliation:

1. 1Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA

2. 2Department of Internal Medicine, Kalmar County Hospital, Kalmar, Sweden

3. 3Department of Clinical Sciences Lund, Section for Oncology and Pathology, Lund University, Lund, Sweden

4. 4Department of Oncology, Skane University Hospital, Lund, Sweden

5. 5Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, PA

6. 6Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY

7. 7Division of Hematology, Mayo Clinic, Rochester, MN

8. 8Division of Hematology and Center of Excellence in Translational Hematology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

9. 9Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

10. 10Department of Medicine, Christiana Care, Newark, DE

11. 11Division of Hematologic Malignancies, Thomas Jefferson University, Philadelphia, PA

12. 12Department of Medicine, Massachusetts General Hospital, Boston, MA

13. 13Division of Hematology/Oncology, Department of Medicine, Washington University in St. Louis, St. Louis, MO

14. 14Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA

15. 15Divison of Hematology, The Ohio State University James Comprehensive Cancer Center, Columbus, OH

16. 16Department of Lymphoma-Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

17. 17Division of Hematology/Oncology, Brown University, Providence, RI

18. 18Division of Hematology, University of Colorado Cancer Center, Aurora, CO

19. 19Section of Hematology/Oncology, The University of Chicago, Chicago, IL

20. 20Department of Hematology and Oncology, Ochsner MD Anderson Cancer Center, Jefferson, LA

21. 21Department of Hematologic Oncology, Atrium Health, Levine Cancer Institute, Wake Forest School of Medicine, Charlotte, NC

22. 22Winship Cancer Institute at Emory University, Decatur, GA

23. 23Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN

24. 24Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH

25. 25Division of Blood and Bone Marrow Transplantation, University of California San Diego Moores Cancer Center, San Diego, CA

26. 26Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY

27. 27Division of Hematology/Oncology, Northwell Health Cancer Institute, New Hyde Park, NY

28. 28Division of Hematology/Oncology, University of Vermont Cancer Center, Burlington, VT

Abstract

Abstract Little is known about risk factors for central nervous system (CNS) relapse in mature T-cell and natural killer cell neoplasms (MTNKNs). We aimed to describe the clinical epidemiology of CNS relapse in patients with MTNKN and developed the CNS relapse In T-cell lymphoma Index (CITI) to predict patients at the highest risk of CNS relapse. We reviewed data from 135 patients with MTNKN and CNS relapse from 19 North American institutions. After exclusion of leukemic and most cutaneous forms of MTNKNs, patients were pooled with non-CNS relapse control patients from a single institution to create a CNS relapse–enriched training set. Using a complete case analysis (n = 182), including 91 with CNS relapse, we applied a least absolute shrinkage and selection operator Cox regression model to select weighted clinicopathologic variables for the CITI score, which we validated in an external cohort from the Swedish Lymphoma Registry (n = 566). CNS relapse was most frequently observed in patients with peripheral T-cell lymphoma, not otherwise specified (25%). Median time to CNS relapse and median overall survival after CNS relapse were 8.0 and 4.7 months, respectively. We calculated unique CITI risk scores for individual training set patients and stratified them into risk terciles. Validation set patients with low-risk (n = 158) and high-risk (n = 188) CITI scores had a 10-year cumulative risk of CNS relapse of 2.2% and 13.4%, respectively (hazard ratio, 5.24; 95% confidence interval, 1.50-18.26; P = .018). We developed an open-access web-based CITI calculator (https://redcap.link/citicalc) to provide an easy tool for clinical practice. The CITI score is a validated model to predict patients with MTNKN at the highest risk of developing CNS relapse.

Publisher

American Society of Hematology

Link

https://ashpublications.org/bloodadvances/article-pdf/8/13/3507/2233863/blooda_adv-2024-012800-main.pdf

Reference36 articles.

1. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee;Campo;Blood,2022

2. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms;Alaggio;Leukemia,2022

3. Analysis and prediction of relative survival trends in patients with non-Hodgkin lymphoma in the United States using a model-based period analysis method;Xie;Front Oncol,2022

4. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes;Vose;J Clin Oncol,2008

5. The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project;Bellei;Haematologica,2018